Efgartigimod Mechanism of Action

Efgartigimod is a human IgG1 antibody Fcfragment that has been engineered forincreased affinity to FcRn compared toendogenous IgG and is uniquely composed ofthe only part of the IgG antibody that normallybinds FcRn. Efgartigimod selectively reducesIgG by blocking FcRn-mediated IgG recycling.

Empasiprubart Proposed Mechanism of Action

(1) Efgartigimod and IgG are internalized into the cell

(2) Efgartigimod outcompetes endogenous IgG antibodies and pathogenic IgG autoantibodies for binding to FcRn, due to increased affinity to FcRn

(3) When bound to FcRn, efgartigimod and IgG escape lysosomal degradation

(4) Remaining unbound IgG and efgartigimod are degraded in the lysosome

(5) FcRn and fewer IgGs are recycled back into circulation

Empasiprubart Proposed Mechanism of Action

(1) Efgartigimod and IgG are internalized into the cell

(2) Efgartigimod outcompetes endogenous IgG antibodies and pathogenic IgG autoantibodies for binding to FcRn, due to increased affinity to FcRn

(3) When bound to FcRn, efgartigimod and IgG escape lysosomal degradation

(4) Remaining unbound IgG and efgartigimod are degraded in the lysosome

(5) FcRn and fewer IgGs are recycled back into circulation